Background: Robatumumab (19D12; MK-7454 otherwise known as SCH717454) is a fully human antibody that binds to and inhibits insulin-like growth factor receptor-1 (IGF-1R). This multiinstitutional study (P04720) determined the safety and clinical efficacy of robatumumab in three separate patient groups with resectable osteosarcoma metastases (Group 1), unresectable osteosarcoma metastases (Group 2), and Ewing sarcoma metastases (Group 3).
INTRODUCTION
Insulin-like growth factor receptor-1 (IGF-1R) is a rational target for Ewing sarcoma therapy because IGFR-1R is involved in growth regulation and cell signaling. [1] [2] [3] [4] [5] Indeed, cellular proliferation, metabolism, and resistance to apoptosis of a wide variety of cancers in addition to bone sarcomas involve IGF-1R signals. [6] [7] [8] [9] [10] [11] Wang et al. developed a fully human anti-IGFR-1 antibody (MK-7454 otherwise known as SCH717454; robatumumab) with very high affinity (3.8 pmol/l) for the receptor. This antibody also inhibits proliferation of a number of cell lines in soft agar as well as in vivo in the human ovarian tumor xenograft model. 12 These observations were extended to pediatric cancers including osteosarcoma and Ewing sarcoma in preclinical experiments. 3, 4, 13, 14 About this time, it was shown that improved lymphocyte recovery following chemotherapy was associated with improved prognosis in patients with Ewing sarcoma 15, 16 ; similar observations also have been made for osteosarcoma patients. 17 Thus, better immune function may affect survival in both Ewing sarcoma and osteosarcoma.
Because of the dismal prognosis associated with metastases of osteosarcoma and Ewing sarcoma, [18] [19] [20] [21] the current study was performed to examine the safety and efficacy of robatumumab in patients diagnosed with metastatic osteosarcoma with a low (i.e., resectable metastases) versus high disease burden (i.e., unresectable metastases) as well as metastatic Ewing sarcoma. This multinational clinical trial treated >200 patients with these rare bone sarcomas with robatumumab. The study was terminated early due to reprioritization of the sponsor's oncology product portfolio following the merger/acquisition of Schering Plough and Merck & Co., Inc. (Kenilworth, NJ). At that time, several other IGF-1R phase 2 studies were being conducted and have subsequently published their final results. [1] [2] [3] [4] [5] Nevertheless, at the time of termination, target enrollment in the robatumumab study was complete and patients who had not yet met protocol discontinuation criteria were allowed to continue receiving study therapy and be seen by the investigator according to usual standard of care, provided the investigator felt that such treatment was in the patient's best interest. This report describes the principal results of this large, phase 2A, multicenter study.
METHODS
This was a multicenter study ( 
Study design
Group 1 osteosarcoma patients were 11 years of age or older and had relapsed, resectable recurrences within 6 months of prior definitive treatment after an initial regimen containing a platinum agent and doxorubicin. Group 1 patients were stratified based on number of relapses (1-2 and >2) and randomly assigned in a 1:1 ratio to double-blind treatment with either a very low dose of robatumumab (0.3 mg/kg) or a standard dose (10 mg/kg) prior to resection after the first dose and PET-
CT. This cohort then received subsequent dosing IV over 1 hr every 2 weeks, had tumor resected after second dose of antibody, then continued every 2 week antibody infusions until documented disease progression. If progression occurred in patients randomized to the low dose arm, subsequent treatment with the standard dose was allowed.
Subjects were required to have a tumor sample obtained within 8 months of study entry to assess historical tumor proliferation rate.
The prior surgical specimen was chosen because of not only challenges of getting lung biopsies, but also potential delay in therapy posed by a biopsy requirement in this group of resectable patients would be not allowed for ethical reasons.
Group 2 osteosarcoma patients were 11 years of age or older and had relapsed metastases that were clinically unresectable (e.g., bone, hilar, or too many metastases to justify resection) after an initial regimen containing a platinum agent and doxorubicin. responses were observed among all 54 patients, the null hypothesis (i.e., radiological response rate of ≤5%) was rejected. For Group 3 only, after enrollment of 54 subjects, if ≥5 responses was observed, up to 50 additional evaluable patients were to be enrolled to obtain a more precise estimate of the response rate. A follow-up period of up to 6 months would be required to obtain sufficient efficacy and safety data. During this period, enrollment was to continue.
With respect to secondary endpoints, the Kaplan-Meier method was used to estimate distributions of time to relapse for both doses of robatumumab (Group 1), duration of response (Groups 2 and 3), time to progression (Groups 2 and 3), and overall survival (all groups).
Safety and tolerability were assessed through physical examinations, vital signs, recording of adverse events (AEs) and routine hematology, chemistry, and urinalysis surveillance. AEs were tabulated by treatment using descriptive statistics.
Due to the early termination of the study, predefined efficacy endpoints could not be evaluated. The response rate, the proportion of subjects who achieved CR, PR, or SD, was summarized using descriptive statistics. CR and PR were determined by two observations not less than 4 weeks apart. Kaplan-Meier plot of overall survival was produced for all three groups. For the Ki-67 analysis, it was centrally reviewed and data analyzed the percent positive nuclei change from baseline was calculated for each subject.
Follow-up and lesion measurement
Centrally reviewed radiology data were available in 144 subjects. Survival data were available until April 2012 in all patients and until
December 2013 in patients with prolonged responses. Of six responding patients with Ewing sarcoma, two had infusions for 1 year (USA) and four had infusions stopped in July 2013 after >100 infusions per patient when drug supply was exhausted (non-USA) and their oncologists were contacted for additional details of these remarkable cases. 
Cluster analysis of genes associated with response

RESULTS
Demographics
The median age of the overall population was 20 years (range 9-79 years). Males accounted for 63% (N = 138) and females 37% (N = 81) of the enrolled population. The majority of patients enrolled in this study
were Caucasian (N = 175; 80%). The median body weight was 64 kg. (12) 20 (9) 1 AE = adverse event; SAE = serious adverse event (may or may not be treatment related). 2 Including 1 haemorrhagic shock in 1 patient. 3 Including two thrombocytopenia in one patient, one hyperglycaemia in one patient. 4 Including one anemia in one patient, one arthralgia in one patient, one unilateral blindness in one patient, one anorexia in one patient, one pneumothorax in one patient, one respiratory distress in one patient, one tachycardia in one patient, and three thrombocytopenia in one patient. Values are n (%). Group 1, osteosarcoma with disease resected by day 14 of study; Group 2, unresectable osteosarcoma; Group 3, Ewing sarcoma; AE, adverse event; SAE, serious adverse event (may or may not be treatment related). Table 1 provides the overall disposition of patients in each of the patient groups. Discontinuation due to an AE while on study medication was a rare occurrence (N = 12; 5% across all the groups and <10% within each group). The majority of patients who discontinued treatment did so due to disease progression (80% across all the groups and >65% within each group). Overall the discontinuations and reasons for discontinuation appeared similar across the different patient groups as well as across robatumumab doses within Group 1.
TA B L E 1 Overall patient disposition summarized by group
Patient disposition
Toxicity and tolerance of antibody infusions
Overall 94% of patients experienced one or more AE during this study ( Although patients with Ewing sarcoma (Group 3, 10 mg/kg infusions) had a higher disease burden (unresectable) and relatively poor short-term survival, about 30% were still alive 1.5 years into the study and a minority (N = 6, see Table 4 ) seem to have achieved long-term survival investigators. Treatment-related AEs of Grade 3 or greater had a generally low incidence rate in this study across the patient groups (<15% for all groups). Of the bone sarcoma patients with measurable disease, 42% of them had reportable SAEs the majority of which were disease related and not related to study drug (e.g., abnormal lab tests, pain, fever, unexpected hospitalization). The incidences of drug-related SAEs were low and similar across the groups (3% and 0% for 0.3 and 10 mg/kg doses within Group 1, 6% for Group 2, and 8% for Group 3).
A total of 151 patients died during the study (35 These AEs leading to death were disease related and not drug related.
Ki67 proliferation data
Only a small subset of patients (11/68 [16%]) in Group 1 had
Ki67 data both at baseline and endpoint. Most patients in both dose levels showed either no change or a decrease from baseline in Ki67 staining of tumor samples. Nevertheless, the sample size was not adequate to make definitive conclusions about the effect of robatumumab 0.3 mg/kg and 10 mg/kg on tumor proliferation.
Centrally reviewed tumor response data
Centrally reviewed tumor response data were available in 144 of 219 patients. In Group 1, there were three patients with PRs (one in the 0.3 mg/kg and two in the 10 mg/kg cohort), 17 patients had SD (10 in 0.3 mg/kg and seven in 10 mg/kg), and 11 patients showed documented disease progression (eight in 0.3 mg/kg and three in 10 mg/kg).
Although no objective tumor responses were seen in the unresectable osteosarcoma cohort (Group 2), six patients had SD per RECIST criteria. Twenty-three patients had documented disease progression.
Of the patients with Ewing sarcoma (Group 3), six had PR, 23 SD, and 55 disease progression. The tumor response findings are summarized in Table 3 . 
TA B L E 4 Patients with Ewing sarcoma who experienced prolonged responses after robatumumab
Patient survival
Overall survival is summarized by patient group in Supplementary   Table S1 and Information on these patients is presented in Table 4 .
Genes associated with response and survival to IGF-1R
Gene signatures associated with better overall survival in responders after robatumumab included those related to direct mTOR downregulation, T cells, apoptosis, and downregulation of AKT and NK cells (Table 5) . Notably, IGF-1, IGF1-R expression, indirect mTOR inhibition/suppression genes, pERK, and TH1 cytokines were not different in responders surviving longer (Table 5 ).
DISCUSSION
IGF-1R is an important pathway for growth of Ewing sarcoma and other cancers. IGF-1R signal inhibition was not sufficient to induce durable remissions in most bone sarcoma patients in our study and other single agent studies. 27, 36, 37 In osteosarcoma patients with resectable disease (Group 1), no dose response was detected for Ki-67 proliferation index or number of patients remaining alive after tumor resection. This group had best overall survival (18 months). In the unresectable osteosarcoma (Group 2) cohort, all of these patients had progression of disease by RECIST; no durable remissions were seen. Nevertheless, overall survival was similar for the unresectable osteosarcoma cohort (Group 2)
if not slightly longer than the Ewing sarcoma cohort (8 months vs. 7 months). It would seem that in osteosarcoma metastases, a population of cancer stem cells may escape inhibition of IGF-1R relatively rapidly thereby necessitating other means (e.g., surgery) for achieving durable remissions. 38 The unique long-term follow up that took place in this study permitted us to demonstrate durable remissions (>4 years) in a minority of unresectable patients with Ewing sarcoma. Further, we were able to show that long-term anti-IGF-1R administration (>4 years) was associated with few, if any, long-term side effects resulting from chronic anti-IGF-1R inhibition. In this group of patients, five of six remaining patients had continuous relapse-free remission. One has had surgery for isolated lung metastases once and is currently responding to 1 year of pazopanib for a >1 cm indicator lesion and two smaller indeterminate lesions (Table 5 ).
The combination of anti-IGF-1R antibodies and mTOR inhibition has demonstrated some success in Ewing sarcoma, 39,40 but mucositis is a problem. 41, 42 Morphoproteomic profiling of two patients relapsing after anti-IGF1-R therapy, then following combined anti-IGF-1R
+ mTOR inhibition, showed two potential patterns of escape through AKT and ERK pathways. One patient showed both pAKT and mTOR and the other mTOR activation, which may explain the emergence of resistance after initial anti-IGF-1R therapy. After combined anti-IGF-1R + mTOR inhibition with temsirolimus, a metastasis showed activation of the ERK pathway when resistance emerged. Biomarkers including IGF-2 and IGFBP-2 seem predictive for effects from ganitumab. 11 Indeed, IGF-2 can reverse potent inhibition of angiogenesis by robamutumab, the antibody used in our study. 43 Of the six patients in this study who experienced long-term durable responses, the cluster analysis showed that immune response genes often were differentially expressed in responders versus nonresponders. This is consistent with results previously reported for trastuzumab and suggests that changes in the expression of immune genes may predict response to robatumumab. 44 Synergy of ganitumab and cisplatin against ovarian cancer xenografts was recently shown. 45 Combinations of anti-IGF-1R antibody dalotuzimub and ridaforlimus was very promising in a phase I trial including 10 of 23 patients with breast cancer 46 ; doselimiting toxicities were stomatitis and asthenia. Compared to the gemcitabine control arm (50% 6-month survival), the addition of ganitumab improved survival in pancreas cancer. 47 Although the best combinations remain to be determined, pairing known effective agents against Ewing sarcoma with an IGF-1R antibody would seem to be a very attractive strategy. However, IGF-1R inhibition seems to have no effect on chemotherapy resistance in vitro. 48 Short-term IGF-1R incubation was shown to increase survival kinase AKT and
x-linked inhibitor of apoptosis (XIAP), which is associated with Apo2L/TNF-related apoptosis-inducing ligand (TRAIL) resistance.
However, long-term IGF-1R inhibition resulted in XIAP repression and eventual Apo2L/TRAIL sensitization. 48 Patience with long-term anti-IGF-1R inhibition could be a virtue in therapy of Ewing sarcoma; it is possible that eventual Apo2L/TRAIL sensitization may be important for durable responses in a subset of patients. Thus, not only mTOR inhibition but also a novel agent that can inhibit both the AKT and ERK pathways to result in TRAIL induction may become another means to more effectively inhibit escape without toxicity to normal cells in which TRAIL is not expressed. 49 Indeed, one such agent, Onc201, has recently completed phase I clinical trials as a single agent. 50 The results of our study are subject to the limitation of early study closure before all study data were collected according to the predefined study protocol. Although patients were allowed to continue study treatment at the discretion of the investigator, all study assessments were not completed per protocol hence limiting the ability to make definitive conclusions about the efficacy and safety/tolerability profile of robatumumab in these various osteosarcoma and Ewing sarcoma cohorts. Nevertheless, the study was fully enrolled at the time a decision was made to terminate this study, thus enabling the assessment of the primary efficacy endpoints in two of three patient groups. The 
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